HONG KONG, CHINA--(Marketwired - November 30, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)
AIM/Nasdaq: HCM
Exercise of Share Options by a Person Discharging Managerial Responsibilities
London: Wednesday, November 30, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Responsibilities), has exercised 25,535 share options (granted in 2007 and which are soon due to expire in May 2017) over ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an exercise price of GBP1.535 per share on November 25, 2016. Such Ordinary Shares will be held in the form of American Depositary Shares ("ADSs") each representing one half of one Ordinary Share.
Following the above exercise of options and subject to the completion of allotment, the holding of Dr Su is 25,535 Ordinary Shares, representing approximately 0.04% of the current issued share capital of Chi-Med, which he intends to hold as a long term investment. Additionally Dr Su holds a further 300,000 unexercised options which would represent a further 0.49% of the issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
---------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
---------------------------------------------------------------------------
a)Name Dr Weiguo Su
---------------------------------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a)Position/status Executive Vice President and Chief
Scientific Officer of Chi-Med
---------------------------------------------------------------------------
b)Initial notification/Amendment Initial notification
---------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a)Name Hutchison China MediTech Limited
---------------------------------------------------------------------------
b)LEI N/A
---------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transactions have been conducted
---------------------------------------------------------------------------
a)Description of the financial Ordinary Shares of US$1.00 each in the
instrument, type of instrument form of ADSs each representing one half of
Identification code one Ordinary Share of US$1.00 DI ISIN:
KYG4672N1016 ADS ISIN: US44842L1035
---------------------------------------------------------------------------
b)Nature of the transaction Exercise of share options on November 25,
2016 at a price of GBP1.535 per share.
Such Ordinary Shares will be held in the
form of ADSs.
---------------------------------------------------------------------------
c)Price(s) and volume(s)
------------------------------------------
Price(s) Volume(s)
------------------------------------------
GBP1.535 25,535
------------------------------------------
---------------------------------------------------------------------------
d) Aggregated volume: 25,535
Aggregated information Price information: GBP1.535
-Aggregated volume
-Price
---------------------------------------------------------------------------
e)Date of the transaction 2016-11-25
---------------------------------------------------------------------------
f)Place of the transaction Outside a trading venue
---------------------------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media
Enquiries
anthony.carlisle@cdrconsultancy.c
Anthony Carlisle, +44 7973 611 888 o.uk
Citigate Dewe Rogerson (Mobile)
U.S. Based Media
Enquiries
Brad Miles, +1 (917) 570 7340 bmiles@bmccommunications.com
BMC Communications (Mobile)
Susan Duffy, +1 (917) 499 8887 sduffy@bmccommunications.com
BMC Communications (Mobile)
Investor Relations
Matt Beck, +1 (917) 415 1750 mbeck@troutgroup.com
The Trout Group (Mobile)
David Dible, +44 7967 566 919 david.dible@citigatedr.co.uk
Citigate Dewe Rogerson (Mobile)
Panmure Gordon (UK)
Limited
Richard Gray / +44 (20) 7886 2500
Andrew Potts
